

PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING OUTCOMES
May 2026 PBAC MEETING – Tranche 1 medicines list for the designated registered nurse (RN) prescribing item

Table 1 - Relevant extract of the May 2026 PBAC meeting outcomes table

AGENDA ITEM, FORM(S), STRENGTH(S), SPONSOR	DRUG TYPE AND USE	PURPOSE OF AGENDA ITEM	PBAC OUTCOME
Designated Registered Nurse (RN) Prescribing	Not applicable	To consider the Tranche 1 lists of medicines for designated RN prescribing suitability.	The PBAC recommended that PBS listings for the majority of alimentary tract, cardiovascular system, genitourinary system and antiparasitic medicines (Tranche 1) be amended to add designated registered nurse prescribers as authorised prescribers. The PBAC noted that prescribing will require a prescribing agreement between an individual designated registered nurse prescriber with an authorised health practitioner. The PBAC did not recommend declaring designated registered nurse prescribers as authorised prescribers for a small number of medicines in Tranche 1 for reasons arising from the complexity of the medical condition or where the PBAC considered there to be a significant risk of prescribing outside of the PBS restrictions.

Table 2 – Designated RN prescriber outcomes and rationale for Tranche 1 medicines grouped by ATC body system

ATC body system A - Alimentary tract and metabolism	
A01AB - Antiinfectives and antiseptics for local oral treatment: amphotericin lozenges, nystatin capsules, tablets	
Outcome: Add designated RN prescribers as eligible prescribers	
A01AD - Stomatological preparations - other agents for local oral treatment: benzydamine hydrochloride mouthwash	
Outcome: Add designated RN prescribers as eligible prescribers	
A02BA - Drugs for acid related disorders - H2-receptor antagonists (orally administered): famotidine, nizatidine, ranitidine	
Outcome: Add designated RN prescribers as eligible prescribers	
A02BC - Drugs for acid related disorders - Proton pump inhibitors where nurse practitioners are eligible prescribers (orally administered): esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole	
Outcome: Add designated RN prescribers as eligible prescribers	
A02BD - Combinations for eradication of <i>Helicobacter pylori</i> (orally administered): esomeprazole (&) amoxicillin (&) clarithromycin combination pack	
Outcome: Add designated RN prescribers as eligible prescribers	
A03BA - Drugs for functional gastrointestinal disorders - belladonna alkaloids, tertiary amine: atropine injection, hyoscine butylbromide injection	
Outcome: Add designated RN prescribers as eligible prescribers	

PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING OUTCOMES
May 2026 PBAC MEETING – Tranche 1 medicines list for the designated registered nurse (RN) prescribing item

A03BB - Drugs for functional gastrointestinal disorders - belladonna alkaloids, semisynthetic, quaternary ammonium compounds: hyoscine butylbromide injection
Outcome: Add designated RN prescribers as eligible prescribers
A03FA - Propulsives: domperidone tablets, metoclopramide tablets, ampoules
Outcome: Add designated RN prescribers as eligible prescribers
A04AA - Antiemetics and antinauseants - serotonin (5HT₃) antagonists listed on the General Schedule: granisetron tablets, ondansetron orally disintegrating tablets, tablets, wafers, oral liquid, palonosetron injection, fosnetupitant + palonosetron injection, netupitant + palonosetron capsule
A04AD - Other antiemetics and antinauseants: aprepitant capsules, fosaprepitant injection, prochlorperazine tablets, ampoules
Outcome: Add designated RN prescribers as eligible prescribers
A05AA - Bile acids and derivatives (orally administered): obeticholic acid, ursodeoxycholic acid
Outcome: Add designated RN prescribers as eligible prescribers, with the same conditions nurse practitioners (continuing therapy only)
A05AX - Other drugs for bile therapy: elafibranor tablets
Outcome: Add designated RN prescribers as eligible prescribers, with the same conditions as nurse practitioners (must consult with a gastroenterologist or hepatologist)
A06AB - Drugs for constipation – contact laxatives: bisacodyl suppositories, enteric tablets
A06AD - Drugs for constipation – osmotically acting laxatives: macrogol-3350 powder for oral liquid, macrogol-3350 + sodium chloride + sodium bicarbonate + potassium chloride powder for oral liquid
A06AG - Drugs for constipation – enemas: sodium citrate dihydrate + lauryl sulfoacetate sodium + sorbitol
A06AG - Drugs for constipation – peripheral opioid receptor antagonists: methylnaltrexone vials for injection
Outcome: Add designated RN prescribers as eligible prescribers
A07AA - Intestinal anti-infectives: rifaximin tablets, vancomycin capsules
Outcome: Add designated RN prescribers as eligible prescribers, with the same conditions as nurse practitioners (must consult with a gastroenterologist or hepatologist for rifaximin)
A07CA - Oral rehydration salts: sodium chloride + potassium chloride + glucose monohydrate + sodium acid citrate sachets
Outcome: Add designated RN prescribers as eligible prescribers
A07DA - Antipropulsives: diphenoxylate hydrochloride tablets, loperamide capsules
Outcome: Add designated RN prescribers as eligible prescribers
A07EA - Corticosteroids acting locally: budesonide (modified release capsules, enteric capsules, foam, orally disintegrating tablets), prednisolone administered rectally (enemas, suppositories)

PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING OUTCOMES
May 2026 PBAC MEETING – Tranche 1 medicines list for the designated registered nurse (RN) prescribing item

Outcome: Add designated RN prescribers as eligible prescribers, with the same conditions as nurse practitioners (varies by indication)
A07EC – Aminosalicylic acid and similar agents: balsalazide capsules, mesalazine enteric tablets, modified release granules, suppositories, enemas, modified release tablets, olsalazine capsules, tablets, sulfasalazine tablets
Outcome: Add designated RN prescribers as eligible prescribers, with the same conditions as nurse practitioners (shared care with a medical practitioner)
A09AA – Digestives, including enzyme preparations: pancreatic extract capsules
Outcome: Add designated RN prescribers as eligible prescribers, with the same conditions as nurse practitioners (continuing therapy only)
A10AB – Insulins and analogues for injection – fast acting: insulin aspart, insulin glulisine, insulin lispro, insulin neutral human A10AC – Insulins and analogues for injection – intermediate acting: insulin isophane human, A10AD – Insulins and analogues for injection – intermediate or long-acting combined with fast-acting: insulin aspart + insulin aspart protamine, insulin degludec + insulin aspart, insulin lispro + insulin lispro protamine, insulin neutral human + insulin isophane human A10AE – Insulins and analogues for injection – long-acting: insulin detemir, insulin glargine
Outcome: Add designated RN prescribers as eligible prescribers
Antidiabetic medicines: A10BA - Biguanides: metformin tablets A10BB – Sulfonylureas (orally administered): glipalamide, gliclazide, glimepiride, glipizide A10BD - Combinations of oral blood glucose lowering drugs (orally administered): alogliptin + metformin, dapagliflozin + metformin, dapagliflozin + sitagliptin, empagliflozin + linagliptin, empagliflozin + metformin, linagliptin + metformin, saxagliptin + dapagliflozin, saxagliptin + metformin, sitagliptin + metformin, vildagliptin + metformin A10BF - Alpha glucosidase inhibitors: acarbose tablets A10BG - Thiazolidinediones: pioglitazone tablets A10BH - Dipeptidyl peptidase-4 inhibitors (orally administered): alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin A10BK - Sodium glucose cotransporter-2 inhibitors (orally administered): dapagliflozin, empagliflozin in diabetes, chronic heart failure and chronic kidney
Outcome: Add designated RN prescribers as eligible prescribers
A10BJ - Glucagon-like peptide-1 (GLP-1) analogues: semaglutide injection, dulaglutide injection
Outcome: Exclude designated RN prescribers
Reasons (Tier principle): Risk of prescribing outside the PBS eligibility criteria, leading to significant increased risk of unexpected Government expenditure and use in circumstances not accepted to be cost-effective (Tier 1 principle)

PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING OUTCOMES
May 2026 PBAC MEETING – Tranche 1 medicines list for the designated registered nurse (RN) prescribing item

A11DA – Vitamin B1, plain: thiamine hydrochloride tablets
A12AA – Mineral supplements – calcium: calcium carbonate chewable tablets, calcium carbonate tablets
A12BA – Mineral supplements – potassium: Vitamins and mineral supplements: potassium chloride modified release tablets, potassium chloride + potassium bicarbonate + potassium carbonate effervescent tablets,
A12CC – Other mineral supplements – magnesium: magnesium tablets
Outcome: Add designated RN prescribers as eligible prescribers
A16AA - Other alimentary tract and metabolism products – amino acids and derivatives: betaine powder for oral liquid
Outcome: Add designated RN prescribers as eligible prescribers, with the same conditions as nurse practitioners (must consult a metabolic physician)
A16AX – Various alimentary tract and metabolism products: lumasiran injection
Outcome: Exclude designated RN prescribers
Reasons (Tier principle): Complex medical condition (Tier 1 principle), Very high cost (Tier 2 principle)
A16AX – Various alimentary tract and metabolism products: sapropterin tablets, powder for oral liquid
Outcome: Add designated RN prescribers as eligible prescribers, with the same conditions as nurse practitioners (must consult a metabolic physician)
A16AX – Various alimentary tract and metabolism products: sodium phenylbutyrate granules
Outcome: Add designated RN prescribers as eligible prescribers
A16AX – Various alimentary tract and metabolism products: trientine dihydrochloride capsules
Outcome: Add designated RN prescribers as eligible prescribers, with the same conditions as nurse practitioners (continuing therapy only)
C - Cardiovascular system
C01AA – Digitalis glycosides: digoxin tablets, oral liquid
Outcome: Add designated RN prescribers as eligible prescribers, with the same conditions as nurse practitioners (shared care with a medical practitioner)
C01BA – Antiarrhythmics, class 1a: disopyramide capsules
C01BB – Antiarrhythmics, class 1b: lidocaine hydrochloride ampoules for injection
C01BC – Antiarrhythmics, class 1c: flecainide tablets
C01BD – Antiarrhythmics, class III: amiodarone tablets, sotalol tablets

PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING OUTCOMES
May 2026 PBAC MEETING – Tranche 1 medicines list for the designated registered nurse (RN) prescribing item

Outcome: Exclude designated RN prescribers
Reasons (Tier principle): Complex medical condition (Tier 1 principle)
C01CA – Cardiac stimulants excluding cardiac glycosides – Adrenergic and dopaminergic agents: adrenaline [#] pen device, ampoules (General Schedule listing)
Outcome: Add designated RN prescribers as eligible prescribers, with the same conditions as nurse practitioners (for pen devices, must consult a specialist immunologist, specialist allergist, paediatrician or respiratory physician for initial therapy that is not subsequent to a hospital/emergency department discharge)
C01DA - Organic nitrates: glyceryl trinitrate patches, spray, isosorbide dinitrate sublingual tablets, isosorbide mononitrate modified release tablets
Outcome: Add designated RN prescribers as eligible prescribers
C01DX - Other vasodilators used in cardiac diseases: nicorandil, perhexiline, vericiguat
C01EB - Other cardiac preparations for chronic heart failure: ivabradine
Outcome: Add designated RN prescribers as eligible prescribers, with the same conditions as nurse practitioners (varies by drug and treatment phase)
Antihypertensives: C02AB - Anti-adrenergic agents – centrally acting: methyldopa tablets C02AC - Imidazoline receptor agonists: clonidine tablets, moxonidine tablets C02CA - Alpha-adrenoceptor antagonists: prazosin tablets C02DC - Pyrimidine derivatives: minoxidil tablets C03AA – Low-ceiling diuretics - thiazide plain: hydrochlorothiazide (HTZ) tablets C03AC – Diuretics - high ceiling - sulfonamides, plain: furosemide oral liquid, tablets, ampoules for injection C03BA - Low ceiling diuretics excluding thiazides: chlortalidone tablets, indapamide tablets, modified release tablets C03DA - Aldosterone antagonists: eplerenone tablets, finerenone tablets, spironolactone tablets C03EA - Low ceiling diuretics and potassium sparing agents: amiloride + HTZ tablets C04AX - Other peripheral vasodilators: phenoxylbenzamine capsules C07AA - Beta blocking agents – non-selective: propranolol tablets C07AB - Beta blocking agents – selective: atenolol tablets, bisoprolol fumarate tablets, metoprolol succinate controlled-release tablets, metoprolol tartrate tablets, nebivolol tablets C07AG - Alpha and beta blocking agents: carvedilol tablets, labetalol tablets

PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING OUTCOMES
May 2026 PBAC MEETING – Tranche 1 medicines list for the designated registered nurse (RN) prescribing item

C08CA - Calcium channel blockers – dihydropyridine derivatives: amlodipine tablets, felodipine modified release tablets, lercanidipine tablets, nifedipine modified release tablets
C08DA - Calcium channel blockers – phenylalkylamine derivatives: verapamil tablets, modified release tablets
C08DB - Calcium channel blockers – benzothiazepine derivatives: diltiazem tablets, modified release capsules
C09AA - ACE inhibitors, plain: captopril oral liquid, enalapril tablets, fosinopril tablets, lisinopril tablets, perindopril tablets, quinapril tablets, ramipril tablets, capsules, trandolapril capsules
C09BA - ACE inhibitors and diuretics (tablets): enalapril + HTZ, perindopril + indapamide
C09BB - ACE inhibitors and calcium channel blockers (tablets): lercanidipine + enalapril, perindopril + amlodipine, ramipril + felodipine, trandolapril + verapamil
C09CA - Angiotensin II receptor blockers (ARBs) plain (tablets): candesartan, eprosartan, irbesartan, olmesartan, telmisartan, valsartan
C09DA - ARBS and diuretics (tablets): candesartan + HTZ, eprosartan + HTZ, irbesartan + HTZ, olmesartan + HTZ, telmisartan + HTZ, valsartan + HTZ
C09DB - ARBS and calcium channel blockers (tablets): amlodipine + valsartan, olmesartan + amlodipine, telmisartan + amlodipine
C09DX - ARBS and other combinations (tablets): olmesartan + amlodipine + HTZ, sacubitril + valsartan
Outcome (medicines other than minoxidil, phenoxybenzamine, labetalol): Add designated RN prescribers as eligible prescribers
Outcome (minoxidil, phenoxybenzamine): Add designated RN prescribers as eligible prescribers, with same with the same conditions as nurse practitioners (continuing therapy only)
Outcome (labetalol): Add designated RN prescribers as eligible prescribers, with same with the same conditions as nurse practitioners (shared care with a medical practitioner)
C10AA – HMG CoA reductase inhibitors (tablets): atorvastatin, pravastatin, rosuvastatin, simvastatin
Outcome: Add designated RN prescribers as eligible prescribers
C10AB – Lipid modifying agents, plain fibrates: fenofibrate tablets, gemfibrozil tablets
Outcome: Add designated RN prescribers as eligible prescribers
C10AC – Lipid modifying agents – bile acid sequestrants: colestyramine oral liquid sachets
Outcome: Add designated RN prescribers as eligible prescribers
C10AX – Other lipid modifying agents: evolocumab injection, ezetimibe tablets, inclisiran injection
Outcome (ezetimibe): Add designated RN prescribers as eligible prescribers
Outcome (evolocumab): Add designated RN prescribers as eligible prescribers, with same with the same conditions as nurse practitioners (shared care and continuing therapy only)
Outcome (inclisiran): Add designated RN prescribers as eligible prescribers, with same with the same conditions nurse practitioners (must consult a specialist physician)
C10BA -Combinations of various lipid modifying agents: ezetimibe + atorvastatin tablets, ezetimibe (&) rosuvastatin tablets

PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING OUTCOMES
May 2026 PBAC MEETING – Tranche 1 medicines list for the designated registered nurse (RN) prescribing item

Outcome: Add designated RN prescribers as eligible prescribers
C10BX – Lipid modifying agents in combination with other drugs: amlodipine + atorvastatin tablets
Outcome: Add designated RN prescribers as eligible prescribers
G - Genito-urinary system and sex hormones
G02BB - Intravaginal contraceptives: etonogestrel + ethinylestradiol rings
Outcome: Add designated RN prescribers as eligible prescribers
G02CB – Prolactine inhibitors: bromocriptine tablets, cabergoline tablets
Outcome: Add designated RN prescribers as eligible prescribers
G03AA – Hormonal contraceptives for systemic use - progestogens and estrogens, fixed combinations (tablets): drospirenone + ethinylestradiol, estetrol + drospirenone, levonorgestrel + ethinylestradiol, estradiol + norethisterone, progesterone & estradiol G03AB – Hormonal contraceptives for systemic use - progestogens and estrogens, sequential preparations (tablets): norethisterone + ethinylestradiol, estradiol & estradiol + dydrogesterone, estradiol & estradiol + norethisterone G03AC – Hormonal contraceptives for systemic use – progestogens: drospirenone tablets, etonogestrel implant, levonorgestrel intrauterine drug delivery system, tablets, medroxyprogesterone injection, norethisterone tablets
Outcome: Add designated RN prescribers as eligible prescribers
G03BA - Androgens - 3-oxoandrostens (4) derivatives: testosterone gel, cream, modified release injection
Outcome: Add designated RN prescribers but restrict prescribing to where consultation has occurred with a specialist (who has a prescribing arrangement with the designated RN prescriber) and to where the prescription continues existing testosterone therapy. Reasons (Tier principle): Complex medical conditions (Tier 1 principle)
G03CA – Natural and semi-synthetic estrogens, plain: estradiol gel, pessaries, patches, tablets, estriol cream, pessaries
Outcome: Add designated RN prescribers as eligible prescribers
G03DA - Progestogens - pregnen (4) derivatives: medroxyprogesterone acetate tablets, progesterone capsules, pessaries
Outcome: Add designated RN prescribers as eligible prescribers
G03DB - Progestogens - pregnadien derivatives: dienogest tablets

PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING OUTCOMES
May 2026 PBAC MEETING – Tranche 1 medicines list for the designated registered nurse (RN) prescribing item

Outcome: Add designated RN prescribers as eligible prescribers
G03FA - Progestogens and estrogens, fixed combinations: estradiol + norethisterone patches, progesterone (&) estradiol gel
Outcome: Add designated RN prescribers as eligible prescribers
G03FB - Progestogens and estrogens, sequential preparations: estradiol (&) estradiol + dydrogesterone tablets, estradiol (&) estradiol + norethisterone patches
Outcome: Add designated RN prescribers as eligible prescribers
G03HA – Antiandrogens, plain: cyproterone tablets
Outcome: Add designated RN prescribers as eligible prescribers
G03XB - Progesterone receptor modulators: mifepristone (&) misoprostol tablets
Outcome: Exclude designated RN prescribers
Reasons (Tier principle): Absence of state or territory legislation permitting prescribing (Tier 1 safety principle)
G04BD - Drugs for urinary frequency and incontinence: oxybutynin patches, tablets, propantheline tablets
Outcome: Add designated RN prescribers as eligible prescribers
G04BX - Other urologicals: sodium bicarbonate capsules
Outcome: Add designated RN prescribers as eligible prescribers
G04CA- Drugs for benign prostatic hypertrophy – alpha-adrenoreceptor antagonists: dutasteride + tamsulosin capsules
G04CB - Drugs for benign prostatic hypertrophy – testosterone-5-alpha reductase inhibitors: dutasteride capsules
Outcome: Add designated RN prescribers as eligible prescribers
P - Antiparasitic products, insecticides and repellents
P01AX – Antiprotozoals - other agents against amoebiasis and other protozoal diseases: atovaquone oral liquid
Outcome: Add designated RN prescribers as eligible prescribers
P01BA – Anthelmintics – quinoline derivatives praziquantel tablets
Outcome: Add designated RN prescribers as eligible prescribers

PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) MEETING OUTCOMES
May 2026 PBAC MEETING – Tranche 1 medicines list for the designated registered nurse (RN) prescribing item

P01BB – Antimalarials - biguanides: atovaquone + proguanil tablets
P01BC – Antimalarials - methanolquinolines: quinine tablets
Outcome: Add designated RN prescribers as eligible prescribers
P02CA - Antinematodal agents benzimidazole derivatives: albendazole 200 mg tablets
P02CC - Antinematodal agents - tetrahydropyrimidine derivatives: pyrantel tablets
Outcome: Add designated RN prescribers as eligible prescribers
P02CF – Avermectines: ivermectin tablets
Outcome: Add designated RN prescribers as eligible prescribers
P03AC - Ectoparasiticides, including scabies - pyrethrines: permethrin cream
Outcome: Add designated RN prescribers as eligible prescribers

Tier 1, Tier 2 principles – refer to [December 2025 PBAC meeting outcome statement](#)

#adrenaline nasal spray not PBS-listed at the time of May 2026 PBAC meeting